Eli Lilly secures first-mover advantage with opforglipron approval in China
NVO Novo Nordisk ADR
$41.09 +0.96%
View chart & analysis → - 1Eli Lilly's opforglipron has received approval in China.
- 2Eli Lilly recorded $24.4 billion in revenue for the third quarter, achieving a 39% revenue growth rate for the third quarter.
- 3J.P. Morgan projected that annual sales of GLP-1 weight management treatments in China could reach $4.5 billion over the next 5 to 7 years.
So what's the key point?
Eli Lilly's obesity treatment has received sales permission in China. This creates an opportunity to generate significant revenue in the Chinese market in the future.
Source Stocktwits +1 · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.